AstraZeneca has said it hopes to start distributing Oxford University’s Covid-19 vaccine by the end of 2020, says Samuel Lovett in The Independent. Preliminary trial results revealed that it induces a “strong immune response within humans” and “appears to be safe”. More detailed results for this vaccine are expected to be available between September and November. Meanwhile, the company has struck deals with the UK, France, Germany and the US to deliver supplies of the vaccine, and will start manufacturing it even before trials finish, with the aim of making two billion doses.
The results may be positive enough to continue with trials, but they “weren’t enough to convince the market”, says Bloomberg. AstraZeneca’s shares fell back early this week. Good news had been “widely expected”, while there are also concerns over whether its vaccine can match the progress seen at rival companies such as Pfizer, BioNtech SE and Moderna. The decision to prioritise a two-dose regime (rather than a single injection) and the fact that the end-of-year deadline is later than the previous promise of a September delivery are also “dampening” some of the enthusiasm.
Hedging bets
In a reminder that AstraZeneca is not the only company close to bringing a vaccine to market, even the British government, one of the biggest backers of Oxford University’s research, now seems to be hedging its bets by working with rivals, says The Daily Telegraph. Having previously agreed to buy 100 million doses of the AstraZeneca vaccine, it has signed additional deals to “secure 90 million doses of two possible Covid-19 vaccines from the Pfizer and BioNTech alliance and French group Valneva”. This could rise to 140 million doses if the Valneva vaccine proves to be “effective and suitable”.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Betting on vaccines from more than one company is an approach investors should adopt too, says Lex in the Financial Times. Formerly considered a “neglected Cinderella industry”, vaccines have “never been so hot”. But there are 170 Covid-19 vaccines in development, so many “also-rans” will inevitably suffer from “irrevocable losses”. Investors should back different approaches to “spread risk”. In any case, the need for “multiple success stories” means that this “is not a winner-takes-all market”, with rewards likely to be spread across multiple firms.
Investors should also note that even if they do manage to bet on a winner, “sales and profits might not flow as much as hoped”, says Charley Grant in The Wall Street Journal. Given that the drug industry will want to avoid “heavy scrutiny” over its pricing practices during the upcoming US election, it will be under pressure to price a vaccine “modestly”. More broadly, the “euphoric trading” that has seen the share price of biotech companies such as Moderna triple means that “caution is always warranted”.
-
Chen Zhi: the kingpin of a global conspiracyChen Zhi appeared to be a business prodigy investing in everything from real estate to airlines. Prosecutors allege he is the head of something more sinister
-
Canadian stocks for a new era of deglobalisationGreg Eckel, portfolio manager at Canadian General Investments, selects three Canadian stocks
-
Chen Zhi: the kingpin of a global conspiracy
Chen Zhi appeared to be a business prodigy investing in everything from real estate to airlines. Prosecutors allege he is the head of something more sinister
-
Canada will be a winner in this new era of deglobalisation and populism
Greg Eckel, portfolio manager at Canadian General Investments, selects three Canadian stocks
-
Jim O’Neill on nearly 25 years of the BRICSJim O’Neill, who coined the acronym BRICS in 2001, tells MoneyWeek how the group is progressing
-
Circle sets a new gold standard for cryptocurrenciesCryptocurrencies have existed in a kind of financial Wild West. No longer – they are entering the mainstream, and US-listed Circle is ideally placed to benefit
-
8 of the best converted industrial properties for saleThe best converted industrial properties for sale – from a Victorian railway station in Norfolk to a Grade II-listed former water tower with views of the River Alde
-
More clouds gather over renewable energy trusts – is there any hope for the sector?The outlook for renewable energy trusts has gone from bad to worse this year, with the industry being caught in a 'perfect storm'
-
Should ISA investors be forced to hold UK shares?The UK government would like ISA investors to hold more UK stocks – but many of us are already overexposed
-
Why Scotland's proposed government bonds are a terrible investmentOpinion Politicians in Scotland pushing for “kilts” think it will strengthen the case for independence and boost financial credibility. It's more likely to backfire
